ST. PETERSBURG, Fla. & IRVINE, Calif.--(BUSINESS WIRE)--The Women’s Tennis Association (WTA) and Masimo (NASDAQ: MASI) announced
today that the WTA’s Sport Sciences and Medicine (SS&M) team will
immediately begin using Masimo MightySat™ as part of their mission to
provide comprehensive care for athletes on the women’s professional
tennis circuit.

MightySat is a fingertip pulse oximeter designed for general wellness
and health applications including sports, fitness, and relaxation
management. MightySat provides noninvasive measurements of oxygen
saturation (SpO2), pulse rate (PR), perfusion index (Pi), PVi®
(studies show changes in PVi may indicate changes in hydration,
breathing effort, perfusion, or other factors1-3) and RRp™
(respiration rate based on the plethysmographic waveform). MightySat
features Masimo SET® Measure-through Motion and Low
Perfusion™ pulse oximetry. MightySat displays all noninvasive
measurements in real time, and users can also display and track their
data through the Masimo Personal Health app for iOS® and
Android® compatible devices.

The WTA SS&M team’s primary health care providers (PHCPs—licensed
physical therapists and certified athletic trainers) will use MightySat
at WTA tournament events to help support the general health, wellness,
and fitness of elite women's tennis players. “We’re fortunate to have
this new technology in the training room and on the court at the WTA.
This equipment will aid our PHCPs in assessing player health and allow
them to better service the immediate needs of our athletes,” said
Kathleen Stroia, SVP SS&M and Transitions for the WTA.

“We have been encouraged by the feedback we have received from elite
athletes and trainers about how MightySat helps them improve their
health and performance. For example, they use Masimo’s unique accuracy
to decide on how hard to train,” said Joe Kiani, Founder and CEO of
Masimo. “We are excited to work with the WTA to help them use Masimo’s
breakthrough noninvasive technologies to make a meaningful difference in
women’s tennis. We have long been big fans of the sport and are excited
to help these peak performing athletes reach even greater heights.”

MightySat is intended for general wellness and health applications. For
medical applications, Masimo offers MightySat Rx, which is available to
medical professionals.

The WTA is the global leader in women’s professional sport with more
than 2,500 players representing nearly 100 nations competing for a
record $146 million in prize money. The 2018 WTA competitive season
includes 54 events and four Grand Slams in 30 countries. In 2017, the
WTA was watched around the world by a total TV audience of 500 million.
The 2018 WTA competitive season concludes with the BNP Paribas WTA
Finals Singapore presented by SC Global from October 21-28, 2018 and the
Hengqin Life WTA Elite Trophy in Zhuhai, China from October 30-November
4, 2018. Further information on the WTA can be found at www.wtatennis.com,
facebook.com/WTA and twitter.com/WTA.

About Masimo

Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. Masimo SET® has also been
shown to help clinicians reduce severe retinopathy of prematurity in
neonates,1 improve CCHD screening in newborns,2
and, when used for continuous monitoring with Masimo Patient SafetyNet™*
in post-surgical wards, reduce rapid response activations and costs.3,4,5
Masimo SET® is estimated to be used on more than 100 million
patients in leading hospitals and other healthcare settings around the
world,6 and is the primary pulse oximetry at 17 of the top 20
hospitals listed in the 2017-18 U.S. News and World Report Best
Hospitals Honor Roll.7 In 2005, Masimo introduced rainbow®
Pulse CO-Oximetry technology, allowing noninvasive and continuous
monitoring of blood constituents that previously could only be measured
invasively, including total hemoglobin (SpHb®), oxygen
content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin
(SpMet®), Pleth Variability Index (PVi®), and more
recently, Oxygen Reserve Index (ORi™), in addition to SpO2,
pulse rate, and perfusion index (Pi). In 2014, Masimo introduced Root®,
an intuitive patient monitoring and connectivity platform with the
Masimo Open Connect® (MOC-9®) interface, enabling
other companies to augment Root with new features and measurement
capabilities. Masimo is also taking an active leadership role in mHealth
with products such as the Radius-7® wearable patient monitor,
iSpO2® pulse oximeter for smartphones, and the
MightySat™ fingertip pulse oximeter. Additional information about Masimo
and its products may be found at www.masimo.com.
Published clinical studies on Masimo products can be found at http://www2.masimo.com/evidence/featured-studies/feature/.

ORi has not received FDA 510(k) clearance and is not available for sale
in the United States.

*The use of the trademark Patient SafetyNet is under license from
University HealthSystem Consortium.

This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
effectiveness of Masimo MightySat™ and SET®. These
forward-looking statements are based on current expectations about
future events affecting us and are subject to risks and uncertainties,
all of which are difficult to predict and many of which are beyond our
control and could cause our actual results to differ materially and
adversely from those expressed in our forward-looking statements as a
result of various risk factors, including, but not limited to: risks
related to our assumptions regarding the repeatability of clinical
results; risks related to our belief that Masimo's unique noninvasive
measurement technologies, including Masimo MightySat and SET®,
contribute to positive clinical outcomes and patient safety; risks
related to our belief that Masimo noninvasive medical breakthroughs
provide cost-effective solutions and unique advantages; as well as other
factors discussed in the "Risk Factors" section of our most recent
reports filed with the Securities and Exchange Commission ("SEC"), which
may be obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.